Cargando…
A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19
Physical interactions between viral and host proteins are responsible for almost all aspects of the viral life cycle and the host’s immune response. Studying viral-host protein-protein interactions is thus crucial for identifying strategies for treatment and prevention of viral infection. Here, we u...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176654/ https://www.ncbi.nlm.nih.gov/pubmed/35677070 http://dx.doi.org/10.21203/rs.3.rs-1354127/v2 |
_version_ | 1784722711496359936 |
---|---|
author | Zhou, Yadi Liu, Yuan Gupta, Shagun Paramo, Mauricio I. Hou, Yuan Mao, Chengsheng Luo, Yuan Judd, Julius Wierbowski, Shayne Bertolotti, Marta Nerkar, Mriganka Jehi, Lara Drayman, Nir Nicolaescu, Vlad Gula, Haley Tay, Savaş Randall, Glenn Lis, John T. Feschotte, Cédric Erzurum, Serpil C. Cheng, Feixiong Yu, Haiyuan |
author_facet | Zhou, Yadi Liu, Yuan Gupta, Shagun Paramo, Mauricio I. Hou, Yuan Mao, Chengsheng Luo, Yuan Judd, Julius Wierbowski, Shayne Bertolotti, Marta Nerkar, Mriganka Jehi, Lara Drayman, Nir Nicolaescu, Vlad Gula, Haley Tay, Savaş Randall, Glenn Lis, John T. Feschotte, Cédric Erzurum, Serpil C. Cheng, Feixiong Yu, Haiyuan |
author_sort | Zhou, Yadi |
collection | PubMed |
description | Physical interactions between viral and host proteins are responsible for almost all aspects of the viral life cycle and the host’s immune response. Studying viral-host protein-protein interactions is thus crucial for identifying strategies for treatment and prevention of viral infection. Here, we use high-throughput yeast two-hybrid and affinity purification followed by mass spectrometry to generate a comprehensive SARS-CoV-2-human protein-protein interactome network consisting of both binary and co-complex interactions. We report a total of 739 high-confidence interactions, showing the highest overlap of interaction partners among published datasets as well as the highest overlap with genes differentially expressed in samples (such as upper airway and bronchial epithelial cells) from patients with SARS-CoV-2 infection. Showcasing the utility of our network, we describe a novel interaction between the viral accessory protein ORF3a and the host zinc finger transcription factor ZNF579 to illustrate a SARS-CoV-2 factor mediating a direct impact on host transcription. Leveraging our interactome, we performed network-based drug screens for over 2,900 FDA-approved/investigational drugs and obtained a curated list of 23 drugs that had significant network proximities to SARS-CoV-2 host factors, one of which, carvedilol, showed promising antiviral properties. We performed electronic health record-based validation using two independent large-scale, longitudinal COVID-19 patient databases and found that carvedilol usage was associated with a significantly lowered probability (17%−20%, P < 0.001) of obtaining a SARS-CoV-2 positive test after adjusting various confounding factors. Carvedilol additionally showed anti-viral activity against SARS-CoV-2 in a human lung epithelial cell line [half maximal effective concentration (EC(50)) value of 4.1 μM], suggesting a mechanism for its beneficial effect in COVID-19. Our study demonstrates the value of large-scale network systems biology approaches for extracting biological insight from complex biological processes. |
format | Online Article Text |
id | pubmed-9176654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Journal Experts |
record_format | MEDLINE/PubMed |
spelling | pubmed-91766542022-06-09 A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19 Zhou, Yadi Liu, Yuan Gupta, Shagun Paramo, Mauricio I. Hou, Yuan Mao, Chengsheng Luo, Yuan Judd, Julius Wierbowski, Shayne Bertolotti, Marta Nerkar, Mriganka Jehi, Lara Drayman, Nir Nicolaescu, Vlad Gula, Haley Tay, Savaş Randall, Glenn Lis, John T. Feschotte, Cédric Erzurum, Serpil C. Cheng, Feixiong Yu, Haiyuan Res Sq Article Physical interactions between viral and host proteins are responsible for almost all aspects of the viral life cycle and the host’s immune response. Studying viral-host protein-protein interactions is thus crucial for identifying strategies for treatment and prevention of viral infection. Here, we use high-throughput yeast two-hybrid and affinity purification followed by mass spectrometry to generate a comprehensive SARS-CoV-2-human protein-protein interactome network consisting of both binary and co-complex interactions. We report a total of 739 high-confidence interactions, showing the highest overlap of interaction partners among published datasets as well as the highest overlap with genes differentially expressed in samples (such as upper airway and bronchial epithelial cells) from patients with SARS-CoV-2 infection. Showcasing the utility of our network, we describe a novel interaction between the viral accessory protein ORF3a and the host zinc finger transcription factor ZNF579 to illustrate a SARS-CoV-2 factor mediating a direct impact on host transcription. Leveraging our interactome, we performed network-based drug screens for over 2,900 FDA-approved/investigational drugs and obtained a curated list of 23 drugs that had significant network proximities to SARS-CoV-2 host factors, one of which, carvedilol, showed promising antiviral properties. We performed electronic health record-based validation using two independent large-scale, longitudinal COVID-19 patient databases and found that carvedilol usage was associated with a significantly lowered probability (17%−20%, P < 0.001) of obtaining a SARS-CoV-2 positive test after adjusting various confounding factors. Carvedilol additionally showed anti-viral activity against SARS-CoV-2 in a human lung epithelial cell line [half maximal effective concentration (EC(50)) value of 4.1 μM], suggesting a mechanism for its beneficial effect in COVID-19. Our study demonstrates the value of large-scale network systems biology approaches for extracting biological insight from complex biological processes. American Journal Experts 2022-06-07 /pmc/articles/PMC9176654/ /pubmed/35677070 http://dx.doi.org/10.21203/rs.3.rs-1354127/v2 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Article Zhou, Yadi Liu, Yuan Gupta, Shagun Paramo, Mauricio I. Hou, Yuan Mao, Chengsheng Luo, Yuan Judd, Julius Wierbowski, Shayne Bertolotti, Marta Nerkar, Mriganka Jehi, Lara Drayman, Nir Nicolaescu, Vlad Gula, Haley Tay, Savaş Randall, Glenn Lis, John T. Feschotte, Cédric Erzurum, Serpil C. Cheng, Feixiong Yu, Haiyuan A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19 |
title | A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19 |
title_full | A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19 |
title_fullStr | A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19 |
title_full_unstemmed | A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19 |
title_short | A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19 |
title_sort | comprehensive sars-cov-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176654/ https://www.ncbi.nlm.nih.gov/pubmed/35677070 http://dx.doi.org/10.21203/rs.3.rs-1354127/v2 |
work_keys_str_mv | AT zhouyadi acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT liuyuan acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT guptashagun acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT paramomauricioi acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT houyuan acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT maochengsheng acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT luoyuan acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT juddjulius acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT wierbowskishayne acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT bertolottimarta acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT nerkarmriganka acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT jehilara acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT draymannir acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT nicolaescuvlad acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT gulahaley acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT taysavas acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT randallglenn acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT lisjohnt acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT feschottecedric acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT erzurumserpilc acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT chengfeixiong acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT yuhaiyuan acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT zhouyadi comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT liuyuan comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT guptashagun comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT paramomauricioi comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT houyuan comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT maochengsheng comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT luoyuan comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT juddjulius comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT wierbowskishayne comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT bertolottimarta comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT nerkarmriganka comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT jehilara comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT draymannir comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT nicolaescuvlad comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT gulahaley comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT taysavas comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT randallglenn comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT lisjohnt comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT feschottecedric comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT erzurumserpilc comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT chengfeixiong comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 AT yuhaiyuan comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19 |